Exelixis, Inc. $EXEL Position Trimmed by Danske Bank A S

Key Points

• Danske Bank A/S drastically cut its position in Exelixis by 99.4% in Q4, selling 234,545 shares and retaining just 1,500 shares valued at about $66,000.
• Exelixis beat Q1 estimates (EPS $0.87 vs. $0.75; revenue $610.8M) and announced a $750M share buyback plus a December PDUFA timeline for zanzalintinib, triggering multiple analyst price-target upgrades.
• Insiders sold a total of 362,849 shares worth about $15.9M last quarter — including sales by SVP Brenda Hefti and CFO Christopher Senner — leaving insiders with roughly 2.6% ownership.

Danske Bank A S lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 99.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,500 shares of the biotechnology company's stock after selling 234,545 shares during the quarter. Danske Bank A S's holdings in Exelixis were worth $66,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of EXEL. Richardson Financial Services Inc. lifted its holdings in shares of Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company's stock valued at $25,000 after buying an additional 292 shares during the last quarter. Anchor Investment Management LLC lifted its holdings in shares of Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company's stock valued at $25,000 after buying an additional 500 shares during the last quarter. Root Financial Partners LLC acquired a new stake in shares of Exelixis during the 3rd quarter valued at about $28,000. Activest Wealth Management acquired a new stake in shares of Exelixis during the 4th quarter valued at about $32,000. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company's stock valued at $34,000 after buying an additional 773 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Insider Transactions at Exelixis

In related news, SVP Brenda Hefti sold 18,669 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $821,622.69. Following the completion of the sale, the senior vice president directly owned 96,512 shares in the company, valued at approximately $4,247,493.12. The trade was a 16.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher J. Senner sold 30,617 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.67, for a total value of $1,337,044.39. Following the completion of the sale, the chief financial officer owned 976,092 shares of the company's stock, valued at approximately $42,625,937.64. This trade represents a 3.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 362,849 shares of company stock worth $15,917,463. 2.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

EXEL has been the subject of several research reports. Stifel Nicolaus lifted their price target on Exelixis from $44.00 to $47.00 and gave the company a "hold" rating in a report on Wednesday. Weiss Ratings reiterated a "buy (b)" rating on shares of Exelixis in a report on Thursday, January 22nd. Truist Financial upgraded Exelixis to a "strong-buy" rating in a report on Monday, April 27th. Barclays lifted their price target on Exelixis from $44.00 to $45.00 and gave the company an "equal weight" rating in a report on Monday, April 20th. Finally, Zacks Research lowered Exelixis from a "strong-buy" rating to a "hold" rating in a report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Exelixis has an average rating of "Hold" and a consensus target price of $47.83.

Key Headlines Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q1 beat and large buyback — Exelixis reported stronger-than-expected Q1 EPS and net income and launched a new $750M share repurchase program, which management says will drive EPS accretion and supports shareholder returns. Why Exelixis (EXEL) Is Up 9.0% After Strong Q1 2026 Earnings And New Buyback Program
• Positive Sentiment: Expanded buyback & PDUFA timing for zanzalintinib — Company disclosed the $750M authorization and outlined a December PDUFA timeline for a colorectal cancer filing for zanzalintinib (ZANZA), adding optionality to future revenue. Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback
• Positive Sentiment: Analyst bullishness and price-target increases — Multiple firms raised targets (HC Wainwright to $56, TD Cowen to $55 and others raising to ~$50–$56), signaling confidence in cabozantinib momentum and buyback-driven EPS. Benzinga: HC Wainwright price target raise
• Neutral Sentiment: Investor events scheduled — Management will host fireside chats at major investor conferences in May (BofA, RBC, Stifel), providing additional opportunities for guidance and Q&A that could influence near-term sentiment. Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
• Neutral Sentiment: Mixed analyst posture — Morgan Stanley nudged its target to $50 but kept an Equal-Weight/Hold stance, and Stifel raised a target modestly; these show cautious optimism but not unanimous buy conviction. Exelixis NASDAQ: EXEL Price Target Raised to $50.00 at Morgan Stanley
• Negative Sentiment: Zanzalintinib/regulatory and pipeline risks flagged — Management and analysts flagged risks around ZANZA development and regulatory timelines on the earnings call, which could add binary risk to forward valuation. Exelixis Earnings Call Highlights Growth And ZANZA Risks
• Negative Sentiment: Sales mix and revenue nuance — Some coverage notes cabozantinib (Cabometyx) growth is solid but trailing certain estimates and revenue miss signals modest near-term commercial headwinds that may temper multiple expansion. EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
• Negative Sentiment: Some cautious analyst views remain — Wells Fargo’s equal-weight target implies downside vs. current levels, reflecting divergent street views that can amplify volatility. Benzinga: Wells Fargo price target note

Exelixis Stock Performance

EXEL opened at $46.21 on Friday. The business has a 50 day moving average price of $43.44 and a 200 day moving average price of $42.97. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $49.62. The firm has a market cap of $11.61 billion, a P/E ratio of 15.35, a price-to-earnings-growth ratio of 1.09 and a beta of 0.38.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. During the same period in the previous year, the company earned $0.55 EPS. The company's revenue for the quarter was up 10.0% on a year-over-year basis. As a group, analysts anticipate that Exelixis, Inc. will post 3.07 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.